Rich Whitworth is the Editor in Chief of Pharmaceutical Technology Europe.
Israel-based Teva Industries seals deal to acquire Cephalon for $6.8 billion.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva